Monograph Series on Aging-related Diseases: X. Prostate Cancer

Chronic Diseases in Canada

Volumn 19, Issue 1, 1998, Pages 1-18

  Ellison, Larry F ^a   Stokes, Julie ^a,b   Gibbons, Laurie ^a   Lindsay, Joan ^b   Levy, Isra ^a   Morrison, Howard ^a  

^a LAB CENTRE FOR DISEASE CONTROL   (Canada)

^b Health Promotion and Programs Branch   (Canada)

Author keywords

Canada; Diagnosis; Morbidity; Mortality; Prostatic neoplasms; Risk factors; Screening; Treatment

Indexed keywords

AGED; AGING; CANADA; HUMAN; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; PROSTATE TUMOR; REVIEW; RISK FACTOR;

AGED; AGING; CANADA; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0031627139     PISSN: 02288699     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (239)

1. Seidman-Ripley J, Huang J. Monograph series on aging-related diseases: IV. Benign prostatic hyperplasia (or hypertrophy). Chronic Dis Can 1993;14(4):131-7.
2. Morgan P. The Canadian Medical Association home medical encyclopedia. Montreal: Reader's Digest Association (Canada) Ltd, 1992:830.
3. Congress of the United States, Office of Technology Assessment. Costs and effectiveness of prostate cancer screening in elderly men. Bethesda (MA): Office of Technology Assessment, 1995.
4. Watanabe H. Natural history of benign prostatic hypertrophy. Ultrasound Med Biol 1986;12:567-71.
5. Walsh PC. Benign prostatic hyperplasia. In: Harrison JH, editor. Campbell's urology. 5th ed. Philadelphia: WB Saunders, 1986:1248-65.
6. Berkow R, Fletcher AJ. The Merck manual of diagnosis and therapy. 16th ed. Rahway (NJ): Merck Research Laboratories, 1992:1750.
7. Brawn PN. Adenosis of the prostate: a dysplastic lesion that can be confused with prostate adenocarcinoma. Cancer 1982;49:826-33.
8. Bostwick DG. Premalignant lesions of the prostate. Semin Diagn Pathol 1988;5:240-53.
9. Haggman MJ, Macoska JA, Wojno KJ, Oesterling JE. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol 1997;158:12-22.
10. Gaudin PB, Epstein JI. Adenosis of the prostate: histologic features in transurethral resection specimens. Am J Surg Pathol 1994;18:863-70.
11. Bostwick DG. High grade prostatic intraepithelial neoplasia. the most likely precursor of prostate cancer. Cancer 1995;75:1823-36.
12. Brawer MK, Bigler SA, Sohlberg OE, Nagle RB, Lange PH. Significance of prostatic intraepithelial neoplasia on prostate needle biopsy. Urology 1991;38:103-7.
13. Weinstein MH, Epstein JI. Significance of high-grade intraepithelial neoplasia on needle biopsy. Hum Pathol 1993;24:624-9.
14. Keetch DW, Humphrey P, Stahl D, Smith DS, Catalona WJ. Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 1995;154:347-51.
15. Davidson D, Bostwick DG, Qian J, et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol 1995;154:1295-9.
16. Berner A, Skjorten FJ, Fossa SD. Follow-up of prostatic intraepithelial neoplasia. Eur Urol 1996;30:256-60.
17. Kovi J, Mostofi FK, Heshmat MY, Enterline JP. Large acinar atypical hyperplasia and carcinoma of the prostate. Cancer 1988;61:555-61.
18. Sakr WA, Haas GP, Cassin BJ, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379-85.
19. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-43.
20. Klotz LH. Managing prostate cancer. Toronto: Canadian Urologic Oncology Group, Grosvenor House Press, 1992.
21. National Cancer Institute of Canada. Canadian cancer statistics 1996. Toronto: NCIC, 1996.
22. Jewett HJ. The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 1975;1:105-24.
23. Prostate. In: Beahrs OH, et al, editors. Manual for staging of cancer / American Joint Committee on Cancer. 4th ed. Philadelphia: JB Lippincott Co, 1992:181-3.
24. Jones WG, Smith PH. Cancer of the prostate. In: Love RR, et al, editors. Manual of clinical oncology. 6th ed. Springer Verlag, 1994:413.
25. Murphy WM. Urological pathology. WB Saunders, 1989:181.
26. PDQ United States National Cancer Institute Information Associate Program, 1997. [For further information contact PDQ, 9030 Old Georgetown Road, Bethesda, Maryland 20814-1519; Tel: 301-496-7600.]
27. Gittes RF. Carcinoma of the prostate. N Engl J Med 1991;324:236-45.
28. Paulson DF, Maul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2NOMO prostatic adenocarcinoma; long term results. J Urol 1990;144:1180-4.
29. Chodak CW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-8.
30. McNeal JE, Bostwick DG, Kindrachuck RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986;1(8472):60-3.
31. Gleason DF, Mellinger GT. Prediction of prognosis for adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
32. Gleason DF. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia: Lea and Febiger, 1977:171-97.
33. Horash KA. Natural history of prostate cancer: B. Imaging technique, radiotherapy, and management issues. Prog Clin Biol Res 1987;243B:289-320.
34. Morse RM, Resnick MI. Detection of clinically occult prostate cancer. Urol Clin North Am 1990;17:567-74.
35. Thompson IM, Zeidman EJ. Extended follow-up of stage Al carcinoma of prostate. Urology 1989;33:455-8.
36. Roy CR II, Home D, Raife M, Pienkos E. Incidental carcinoma of prostate: long-term follow-up. Urology 1990;36:210-3.
37. Scardino PT. Early detection of prostate cancer. Urol Clin North Am 1989;16:635-55.
38. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 1977;20:680-8.
39. Guileyardo JM, Johnson WD, Welsh RA, Akazaki K, Correa P. Prevalence of latent prostate carcinoma in two U.S. populations. J Natl Cancer Inst 1980;65:311-4.
40. Muir C, Waterhouse J, Mack T, et al, editors. Cancer incidence in five continents, Vol V. Lyon, France: International Agency for Research on Cancer, 1987; IARC Scientific Pub No 88.
41. American Cancer Society. Cancer facts and figures - 1997. Atlanta (GA): American Cancer Society, 1997.
42. Parkin DM, Muir CS, Whelan SL, et al, editors. Cancer incidence in five continents, Vol VI. Lyon, France: International Agency for Research on Cancer, 1992; IARC Scientific Pub No 120.
43. Dijkman GA, Debruyne FMJ. Epidemiology of prostate cancer. Eur Urol 1996;30:281-95.
44. National Cancer Institute of Canada. Canadian cancer statistics 1997. Toronto: NCIC, 1997.
45. Morrison HI, MacNeill IB, Miller D, Levy I, Xie L, Mao Y. The impending Canadian prostate cancer epidemic. Can J Public Health 1995;86:274-8.
46. Levy I. Prostate cancer: the epidemiologic perspective. Can J Oncol 1994;(4 Suppl 1):4-7.
47. Statistics Canada. Cancer in Canada 1991. Ottawa, 1995; Cat 82-218.
48. Levy I, Gibbons L, Collins JP, Perkins DG, Mao Y. Prostate cancer trends in Canada: rising incidence or increased detection? Can Med Assoc J 1993;149:617-24.
49. Newman J. Epidemiology, diagnosis and treatment of prostate cancer. Radiol Technol 1996;68:39-64.
50. Higgins ITT. The epidemiology of cancer of the prostate. J Chronic Dis 1975;28:343-8.
51. Ross RK, Schottenfeld D. Prostate cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. 2nd ed. New York: Oxford University Press; 1996:1180-206.
52. Kuroishi T, Hayakawa N, Kurihara M, Aoki K. Cancer mortality in 33 countries of the world (1953-1987). Gann Monograph on Cancer Research 1994;41:167-230.
53. Feightner JW. Screening for prostate cancer. In: Canadian Task Force on the Periodic Health Examination. The Canadian guide to clinical preventive health care. Ottawa: Health Canada, 1994:812-23; Cat H21-117/1994E.
54. Hanash KA. Natural history of prostatic cancer. Prog Clin Biol Res 1987;243B:289-320.
55. Zaridze DG, Boyle P. Cancer of the prostate: epidemiology and aetiology. Br J Urol 1987;59:493-502.
56. Franks LM. Latent carcinoma of the prostate. J Pathol Bacteriol 1954;68:603-16.
57. Dhom G. Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate. J Cancer Res Clin Oncol 1983;106:210-18.
58. Mao Y, Morrison H, Semenciw R, Robson D, Wigle D. The prevalence of cancer in Canada. Can J Public Health 1991;82:61-2.
59. National Cancer Institute of Canada. Canadian cancer statistics 1995. Toronto: NCIC, 1995:64.
60. Cannon L, Bishop DT, Skolnick M, Hunt S, Lyon JL, Smart CR. Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Surv 1982;1:47-69.
61. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and risk of prostate cancer. Prostate 1990;17:337-47.
62. Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR. Familial patterns of prostate cancer: a case-control analysis. J Urol 1991;146:1305-7.
63. Whittemore AS, Wu AH, Kolonel LN, et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 1995;141:732-40.
64. Lesko SM, Rosenberg L, Shapiro S. Family history and prostate cancer risk. Am J Epidemiol 1996;144:1041-7.
65. Ghadirian P, Cadotte M, Lacroix A, Perret C. Family aggregation of cancer of the prostate in Quebec: the tip of the iceberg. Prostate 1991;19:43-52.
66. Fincham SM, Hill GB, Hanson J, Wijayasinghe C. Epidemiology of prostatic cancer: a case-control study. Prostate 1990;17:189-206.
67. McLellan DL, Norman RW. Hereditary aspects of prostate cancer. Can Med Assoc J 1995;153:895-900.
68. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992;89:3367-71.
69. 3 receptors and actions in human prostate cancer cell lines. Endocrinol 1993;132:1952-60.
70. Statistics Canada. Population projections for Canada, provinces and territories, 1989-2011. Ottawa, 1990; Cat 91-520.
71. Stellman SD, Wang QS. Cancer mortality in Chinese immigrants to New York City. Comparison with Chinese in Tianjin and with United States-born Whites. Cancer 1994;73:1270-5.
72. Nomura AMY, Kolonel LN. Prostate cancer: a current perspective. Epidemiol Rev 1991;13:200-27.
73. Carter BS, Carter HB, Isaacs JT. Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate 1990;16:187-97.
74. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993;118:793-803.
75. Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res 1982;42:3232-9.
76. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986;76:45-8.
77. Nomura A, Heilbrun LK, Stemmermann GN, et al. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1988;48:3515-7.
78. Barrett-Conner E, Garland C, McPhillips JB, et al. A prospective, population-based study of androstenedione, estrogens and prostatic cancer. Cancer Res 1990;50:169-73.
79. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 1993;2:27-32.
80. Nomura AMY, Stemmermann GN, Chyou P, Henderson BE, Stanczyk FZ. Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5:621-5.
81. Ross RK, Bernstein L, Lobo RA, et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339:887-9.
82. Meikle AW, Smith JA, Stringham JD. Production, clearance, and metabolism of testosterone in men with prostatic cancer. Prostate 1987;10:25-31.
83. Coleman M, Esteve J, Damiecki P, Arslan A, Renard H, editors. Time trends in cancer incidence and mortality. Lyon: International Agency for Research on Cancer, 1993; IARC Scientific Pub No 121.
84. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968;40:43-68.
85. Locke FB, King H. Cancer mortality risk among Japanese in the United States. J Natl Cancer Inst 1980;65:1149-56.
86. Yu H, Harris RE, Gao YT, Gao R, Wynder EL. Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States. Int J Epidemiol 1991;20:76-81.
87. Blair A, Zahm SH. Cancer among farmers. Occup Med 1991;6:335-54.
88. Morrison H, Savitz D, Semenciw R, et al. Farming and prostate cancer mortality. Am J Epidemiol 1993;137:270-80.
89. Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides (Division of Health Promotion and Disease Prevention, Institute of Medicine). Veterans and agent orange: update 1996. Washington (DC): National Academy Press, 1996.
90. International Agency for Research on Cancer. The rubber industry. Lyon: IARC, 1982; IARC Monographs on the Evaluation of Carcinogenic Risks of Chemicals to Humans, Vol 28.
91. Piscator M. Role of cadmium in carcinogenesis with special reference to cancer of the prostate. Environ Health Perspect 1981;40:107-20.
92. Kerr WK, Keresteci AG, Mayoh H. The distribution of zinc within the human prostate. Cancer 1960;13:550-4.
93. Elghany NA, Schumacher MC, Slattery ML, West DW, Lee JS. Occupation, cadmium exposure, and prostate cancer. Epidemiology 1990;1:107-15.
94. Lee IM, Paffenbarger RS Jr, Hsieh CC. Physical activity and risk of prostatic cancer among college alumni. Am J Epidemiol 1992;135:169-79.
95. Hsing AW, McLaughlin JK, Zheng W, Gao YT, Blot WJ. Occupation, physical activity, and risk of prostate cancer in Shanghai, People's Republic of China. Cancer Causes Control 1994;5:136-40.
96. Albanes D, Blair A, Taylor PR. Physical activity and risk of cancer in the NHANES I population. Am J Public Health 1989;79:744-50.
97. Thune I, Lund E. Physical activity and the risk of prostate and testicular cancer: a cohort study of 53,000 Norwegian men. Cancer Causes Control 1994;5:549-56.
98. Whittemore AS, Paffenbarger RS Jr, Anderson K, Lee JE. Early precursors of site-specific cancers in college men and women. J Natl Cancer Inst 1985;74:43-51.
99. Polednak AP. College athletics, body size, and cancer mortality. Cancer 1976;38:382-7.
100. Paffenbarger RS Jr, Hyde RT, Wing AL. Physical activity and incidence of cancer in diverse populations: a preliminary report. Am J Clin Nutr 1987;45:312-7.
101. Whittemore AS, Kolonel LN, Wu AH, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995;87:652-61.
102. Severson RK, Nomura AMY, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989;49:1857-60.
103. Dosemeci M, Hayes RB, Vetter R, et al. Occupational physical activity, socioeconomic status, and risks of 15 cancer sites in Turkey. Cancer Causes Control 1993;4:313-21.
104. Vena JE, Graham S, Zielzny M, Brasure J, Swanson MK. Occupational exercise and risk of cancer. Am J Clin Nutr 1987;45:318-27.
105. Brownson RC, Chang JC, Davis JR, Smith CA. Physical activity on the job and cancer in Missouri. Am J Public Health 1991;81:639-42.
106. Le Marchand L, Kolonel LN, Yoshizawa CN. Lifetime occupational physical activity and prostate cancer risk. Am J Epidemiol 1991;133:103-11.
107. Talamini R, La Vecchia C, Decarli A, Negri E, Franceschi S. Nutrition, social factors and prostatic cancer in a northern Italian population. Br J Cancer 1986;53:817-21.
108. Severson RK, Grove JS, Nomura AMY, Stemmermann GN. Body mass and prostatic cancer: a prospective study. BMJ 1988;297:713-5.
109. Hayes RB, de Jong FH, Raatgever J, et al. Physical characteristics and factors related to sexual development and behaviour and the risk for prostatic cancer. Eur J Cancer Prev 1992;1:239-45.
110. Mills PK, Beeson WL, Phillips RL, Fraser GE. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 1989;64:598-604.
111. Le Marchand L, Kolonel LN, Wilkens LR, Myers BC, Hirohata T. Animal fat consumption and prostate cancer: a prospective study in Hawaii. Epidemiology 1994;5:276-82.
112. Wynder EL, Mabuchi K, Whitmore WF Jr. Epidemiology of cancer of the prostate. Cancer 1971;28:344-60.
113. Ross RK, Shimizu H, Paganini-Hill A, Honda G, Henderson BE. Case-control studies of prostate cancer in blacks and whites in southern California. J Natl Cancer Inst 1987;78:869-74.
114. Graham S, Haughey B, Marshall J, et al. Diet in the epidemiology of carcinoma of the prostate gland. J Natl Cancer Inst 1983;70:687-92.
115. Kolonel LN, Yoshizawa CN, Hankin JH. Diet and prostatic cancer: a case-control study in Hawaii. Am J Epidemiol 1988;127:999-1012.
116. Garn SM, Leonard WR, Hawthorne VM. Three limitations of the body mass index. Am J Clin Nutr 1986;44:996-7.
117. Kolonel LN. Nutrition and prostate cancer. Cancer Causes Control 1996;7:83-94.
118. Berg JW. Can nutrition explain the pattern of international epidemiology of hormone-dependent cancers? Cancer Res 1975;35:3345-50.
119. Rohan TE, Howe GR, Burch JD, Jain M. Dietary factors and risk of prostate cancer: a case-control study in Ontario, Canada. Cancer Causes Control 1995;6:145-54.
120. West DW, Slattery ML, Robison LM, French TK, Mahoney AW. Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control 1991;2:85-94.
121. Andersson SO, Wolk A, Bergstrom R, et al. Energy, nutrient intake and prostate cancer risk: a population-based case-control study in Sweden. Int J Cancer 1996;68:716-22.
122. Ghadirian P, Lacroix A, Maisonneuve P, et al. Nutrition factors and prostate cancer: a case-control study of French Canadians in Montreal, Canada. Cancer Causes Control 1996;7:428-36.
123. Ohno Y, Yoshida O, Oishi K, Okada K, Yamabe H, Schroeder FH. Dietary β-carotene and cancer of the prostate: a case-control study in Kyoto, Japan. Cancer Res 1988;48:1331-6.
124. Willett WC. Nutritional epidemiology. New York: Oxford University Press, 1990:250.
125. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special references to dietary practices. Int J Cancer 1975;15:617-31.
126. Howell MA. Factor analysis of international cancer mortality data and per capita food consumption. Br J Cancer 1974;29:328-36.
127. Blair A, Fraumeni JF Jr. Geographic patterns of prostate cancer in the United States. J Natl Cancer Inst 1978;61:379-84.
128. Walker ARP, Walker BF, Tsotetsi NG, Sebitso C, Siwedi D, Walker AJ. Case-control study of prostate cancer in black patients in Soweto, South Africa. Br J Cancer 1992;65:438-41.
129. Talamini R, Franceschi S, La Vecchia C, Serraino D, Barra S, Negri E. Diet and prostate cancer: a case-control study in Northern Italy. Nutr Cancer 1992;18:277-86.
130. Mettlin C, Selenskas S, Natarajan N, Huben R. Beta-carotene and animal fats and their relationship to prostate cancer risk. Cancer 1989;64:605-12.
131. Heshmat MY, Kaul L, Kovi J, et al. Nutrition and prostate cancer: a case-control study. Prostate 1985;6:7-17.
132. Schuman LM, Mandel JS, Radke A, Seal U, Halberg F. Some selected features of the epidemiology of prostatic cancer: Minneapolis-St Paul, Minnesota case-control study, 1976-1979. In: Magnus K, editor. Trends in cancer incidence: causes and practical implications. Washington: Hemisphere Publishing Corporation; 1982:345-54.
133. Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993;85:1571-9.
134. Snowden DA, Phillips RL, Choi W. Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol 1984;120:244-250.
135. Hsing AW, McLaughlin JK, Schuman LM, et al. Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res 1990;50:6836-40.
136. Hirayama T. Epidemiology of prostate cancer with special reference to the role of diet. Natl Cancer Inst Monogr 1979;53:149-55.
137. Gann PH, Hennekens CH, Sacks FM, Grodstein F, Giovannucci EL, Stampfer MJ. Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 1994;86:281-6.
138. Kummet T, Moon TE, Meyskens FL Jr. Vitamin A: evidence for its preventive role in human cancer. Nutr Cancer 1983;5:96-106.
139. Hunter D. Biochemical indicators of dietary intake. In: Willett W. Nutritional epidemiology. New York: Oxford University Press; 1990:143-216.
140. Kolonel LN, Hankin JH, Yoshizawa CN. Vitamin A and prostate cancer in elderly men: enhancement of risk. Cancer Res 1987;47:2982-5.
141. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995;87:1767-76.
142. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Vitamin A, β-carotene, and the risk of cancer: a prospective study. J Natl Cancer Inst 1987;79:443-8.
143. Hayes RB, Bogdanovicz J, Schroeder F, et al. Serum retinol and prostate cancer. Cancer 1988;62:2021-6.
144. Hsing AW, Comstock GW, Abbey H, Polk BF. Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer. J Natl Cancer Inst 1990;82:941-6.
145. Knekt P, Aromaa A, Maatela J, et al. Serum vitamin A and subsequent risk of cancer: cancer incidence follow-up of the Finnish Mobile Clinic Health Examination Survey. Am J Epidemiol 1990;132:857-70.
146. Reichman ME, Hayes RB, Ziegler RG, et al. Serum vitamin A and subsequent development of prostate cancer in the First National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Cancer Res 1990;50:2311-5.
147. Ellison LF. Serum vitamin A and prostate cancer [dissertation]. Ottawa: University of Ottawa, 1997.
148. Wald N, Boreham J, Bailey A. Serum retinol and subsequent risk of cancer. Br J Cancer 1986;54:957-61.
149. Nomura AMY, Stemmermann GN, Lee J, Craft NE. Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. Cancer Epidemiol Biomarkers Prev 1997;6:487-91.
150. Olson JA. Vitamin A. In: Ziegler EE, Filer LJ Jr, editors. Present knowledge in nutrition. 7th ed. Washington (DC): International Life Sciences Institute Press; 1996:109-19.
151. Middleton B, Byers T, Marshall J, Graham S. Dietary vitamin A and cancer - a multisite case-control study. Nutr Cancer 1986;8:107-16.
152. Mishina T, Watanabe H, Araki H, Nakao M. Epidemiological study of prostatic cancer by matched-pair analysis. Prostate 1985;6:423-36.
153. Daviglus ML, Dyer AR, Persky V, et al. Dietary beta-carotene, vitamin C, and risk of prostate cancer: results from the Western Electric Study. Epidemiol 1996;7:472-7.
154. Hirayama T. A large scale cohort study on cancer risks by diet - with special reference to the risk reducing effects of green-yellow vegetable consumption. In: Hayashi Y, Nagao M, Sugimura T, et al, editors. Diet, nutrition, and cancer. Proceedings of the 16th International Symposium of the Princess Takamatsu Cancer Research Fund; 1985; Tokyo, Japan. Japan Scientific Society Press, 1986:41-53.
155. Di Mascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys 1989;274:532-8.
156. Clinton SK, Emenhiser C, Schwartz SJ, et al. Cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev 1996;5:823-33.
157. Mangels AR, Holden J, Beecher GR, Forman MR, Lanza E. Carotenoid content of fruits and vegetables: an evaluation of analytic data [published erratum appears in J Am Diet Assoc 1993;93:527]. J Am Diet Assoc 1993;93:284-96.
158. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA 1996;276:1957-63.
159. Comstock GW, Bush TL, Helzlsouer K. Serum retinol, beta-carotene, vitamin E, and selenium as related to subsequent cancer of specific sites. Am J Epidemiol 1992;135:115-21.
160. Knekt P, Aromaa A, Maatela J, et al. Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst 1990;82:864-8.
161. Willett WC, Polk BF, Morris JS, et al. Prediagnostic serum selenium and risk of cancer. Lancet 1983;2:130-4.
162. Kaul L, Heshmat MY, Kovi J, et al. The role of diet in prostate cancer. Nutr Cancer 1987;9:123-8.
163. Bravo MP, Castellanos E, del Rey Calero J. Dietary factors and prostate cancer. Urol Int 1991;46:163-6.
164. Shibata A, Paganini-Hill A, Ross RK, Henderson BE. Intake of vegetables, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among the elderly: a prospective study. Br J Cancer 1992;66:673-9.
165. Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993;2:467-72.
166. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990;10:1307-12.
167. Corder EH, Friedman GD, Vogelman JH, Orentreich N. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev 1995;4:655-9.
168. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5:121-6.
169. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 1995;6:235-9.
170. Schwartz GG. Correspondence re: EH Corder et al, Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2:467-72, 1993. Cancer Epidemiol Biomarkers Prev 1994;3:183-4.
171. 3 concentration. J Clin Invest 1981;67:589-96.
172. Schwartz GG, Hulka BS, Morris D, Mohler JL. Prostate cancer and vitamin (hormone) D: a case-control study. J Urol 1992;147 Suppl:294A.
173. Gordon GG, Altman K, Southren AL, Rubin E, Lieber CS. Effect of alcohol (ethanol) administration on sex-hormone metabolism in normal men. N Engl JMed 1976;295:793-7.
174. Checkoway H, DiFerdinando G, Hulka BS, Mickey DD. Medical, life-style, and occupational risk factors for prostate cancer. Prostate 1987;10:79-88.
175. Hiatt RA, Armstrong MA, Klatsky AL, Sidney S. Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United States). Cancer Causes Control 1994;5:66-72.
176. Yu H, Harris RE, Wynder EL. Case-control study of prostate cancer and socioeconomic factors. Prostate 1988;13:317-25.
177. Slattery ML, West DW. Smoking, coffee, alcohol, tea, caffeine, and theobromine: risk of prostate cancer in Utah (United States). Cancer Causes Control 1993;4:559-63.
178. Adami HO, McLaughlin JK, Hsing AW, et al. Alcoholism and cancer risk: a population-based cohort study. Cancer Causes Control 1992;3:419-25.
179. Tavani A, Negri E, Franceschi S, Talamini R, La Vecchia C. Alcohol consumption and risk of prostate cancer. Nutr Cancer 1994;21:25-31.
180. Van der Gulden JWJ, Verbeek ALM, Kolk JJ. Smoking and drinking habits in relation to prostate cancer. Br J Urol 1994;73:382-9.
181. Cerhan JR, Torner JC, Lynch CF, et al. Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). Cancer Causes Control 1997;8:229-38.
182. Hayes RB, Brown LM, Schoenberg JB, et al. Alcohol use and prostate cancer risk in US blacks and whites. Am J Epidemiol 1996;143:692-7.
183. Andersson SO, Baron J, Bergstrom R, Lindgren C, Wolk A, Adami HO. Lifestyle factors and prostate cancer risk: a case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 1996;5:509-13.
184. Schuman LM, Mandel J, Blackard C, Bauer H, Scarlett J, McHugh R. Epidemiologic study of prostatic cancer: preliminary report. Cancer Treat Rep 1977;61:181-6.
185. Honda GD, Bernstein L, Ross RK, Greenland S, Gerkins V, Henderson BE. Vasectomy, cigarette smoking, and age at first sexual intercourse as risk factors for prostate cancer in middle-aged men. Br J Cancer 1988;57:326-31.
186. Schwartz D, Flamant R, Lellouch J, Denoix PF. Results of a French survey on the role of tobacco, particularly inhalation, in different cancer sites. J Natl Cancer Inst 1961;26:1085-108.
187. Williams RR, Horm JW. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. J Natl Cancer Inst 1977;58:525-47.
188. Niijima T, Kosio K. Incidence of prostatic cancer in Japan and Asia. Scand J Urol Nephrol 1980;55 Suppl:17-21.
189. Newell GR, Fueger JJ, Spitz MR, Babaian RJ. A case-control study of prostate cancer. Am J Epidemiol 1988;130:395-8.
190. Oishi K, Okada K, Yoshida O, et al. Case-control study of prostate cancer in Kyoto, Japan: demographic and some lifestyle risk factors. Prostate 1989;14:117-22.
191. Talamini R, Franceschi S, La Vecchia C, Guarneri S, Negri E. Smoking habits and prostate cancer: a case-control study in northern Italy. Prev Med 1993;22:400-8.
192. Hayes RB, Pottern LM, Swanson GM, et al. Tobacco use and prostate cancer in blacks and whites in the United States. Cancer Causes Control 1994;5:221-6.
193. Kolonel L, Winkelstein W Jr. Cadmium and prostatic carcinoma. Lancet 1977;2:566-7.
194. Siemiatycki J, Krewski D, Franco E, Kaiserman M. Associations between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. Int J Epidemiol 1995;24:504-14.
195. Carstensen JM, Pershagen G, Eklund G. Mortality in relation to cigarette and pipe smoking: 16 years' observations of 25 000 Swedish men. J Epidemiol Community Health 1987;41:166-72.
196. Hammond EC. Smoking in relation to mortality and morbidity: findings in first thirty-four months of follow-up in a prospective study started in 1959. J Natl Cancer Inst 1964;32:1161-88.
197. Weir JM, Dunn JE Jr. Smoking and mortality: a prospective study. Cancer 1970;25:105-12.
198. Coughlin SS, Neaton JD, Sengupta A. Cigarette smoking as a predictor of death from prostate cancer in 348,874 men screened for the Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;143:1002-6.
199. Hsing AW, McLaughlin JK, Hrubec Z, Blot WJ, Fraumeni JF Jr. Tobacco use and prostate cancer: 26-year follow-up of US veterans. Am J Epidemiol 1991;133:437-41.
200. Rodriguez C, Tatham LM, Thun MJ, Calle EE, Heath CW Jr. Smoking and fatal prostate cancer in a large cohort of adult men. Am J Epidemiol 1997;145:466-75.
201. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994;309:901-11.
202. Engeland A, Andersen A, Haldorsen T, Tretli S. Smoking habits and risk of cancers other than lung cancer: 28 years' follow-up of 26,000 Norwegian men and women. Cancer Causes Control 1996;7:497-506.
203. Colditz G. Consensus conference: smoking and prostate cancer. Cancer Causes Control 1996;7:560-2.
204. Key T. Risk factors for prostate cancer. In: Shoebottom E, editor. Preventing prostate cancer: screening versus chemo-prevention. Cold Spring Harbor Laboratory Press, 1995:63-77.
205. Ross RK, Deapen DM, Casagrande JT, Paganini-Hill A, Henderson BE. A cohort study of mortality from cancer of the prostate in Catholic priests. Br J Cancer 1981;43:233-5.
206. Giovannucci E, Tosteson TD, Speizer FE, Ascherio A, Vessey MP, Colditz GA. A retrospective cohort study of vasectomy and prostate cancer in US men. JAMA 1993;269:878-82.
207. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. A prospective cohort study of vasectomy and prostate cancer in US men. JAMA 1993;269:873-7.
208. Sidney S. Vasectomy and the risk of prostatic cancer and benign prostatic hypertrophy. J Urol 1987;138:795-7.
209. Sidney S, Quesenberry CP, Sadler MC, Guess HA, Lydick EG, Cattolica EV. Vasectomy and the risk of prostate cancer in a cohort of multiphasic health-checkup examinees: second report. Cancer Causes Control 1991;2:113-6.
210. John EM, Whittemore AS, Wu AH, et al. Vasectomy and prostate cancer: results from a multiethnic case-control study. J Natl Cancer Inst 1995;87:662-9.
211. Rosenberg L, Palmer JR, Zauber AG, et al. The relation of vasectomy to the risk of cancer. Am J Epidemiol 1994;140:431-8.
212. Hayes RB, Pottern LM, Greenberg R, et al. Vasectomy and prostate cancer in US blacks and whites. Am J Epidemiol 1993;137:263-9.
213. Zhu K, Stanford JL, Daling JR, et al. Vasectomy and prostate cancer: a case-control study in a health maintenance organization. Am J Epidemiol 1996;144:717-22.
214. Ross RK, Paganini-Hill A, Henderson BE. The etiology of prostate cancer: what does the epidemiology suggest? Prostate 1983;4:333-44.
215. Hsing AW, Wang RT, Gu FL. Vasectomy and prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 1994;3:285-8.
216. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. Vasectomy and the risk of prostate cancer. Am J Epidemiol 1990;132:1051-5.
217. Mettlin C, Natarajan N, Huben R. Vasectomy and prostate cancer risk. Am J Epidemiol 1990;132:1056-61.
218. Spitz MR, Fueger JJ, Babaian RJ, Newell GR. Vasectomy and the risk of prostate cancer. Am J Epidemiol 1991;134:108-9.
219. Howards SS, Peterson HB. Vasectomy and prostate cancer: chance, bias, or a causal relationship? JAMA 1993;269:913-4.
220. Sidney S, Quesenberry CP Jr, Sadler MC, Cattolica EV. Vasectomy and increased risk of prostate cancer. JAMA 1993;270:705.
221. Howards SS. Possible biological mechanisms for a relationship between vasectomy and prostatic cancer. Eur J Cancer 1993;29A:1060-62.
222. Freidman GD, Hiatt RA, Quesenberry CP Jr, Selby JV. Case-control study of screening for prostate cancer by digital rectal examinations. Lancet 1991;337:1526-9.
223. Gerber GS, Thompson IM, Thisted R, Chodak GW. Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA 1993;269:61-4.
224. Chamberlin J, Melia J. Screening for prostate cancer. In: Chamberlin J, Moss S, et al, editors. Evaluation of cancer screening. London: Springer-Verlag, 1996:118-35.
225. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994;331:996-1004.
226. Woolf SH. Screening for prostate cancer with prostate-specific antigen. N Engl J Med 1995;333:1401-5.
227. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358-68.
228. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-54.
229. Babaian RJ, Mettlin C, Kane R, et al. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography: findings of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1992;69:1195-2000.
230. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841-5.
231. Mettlin C, Murphy GP, Lee F, et al. Characteristics of prostate cancers detected in a multimodality early detection program. Cancer 1993;72:1701-8.
232. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,650 men. J Urol 1994;151:1283-90.
233. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate specific antigen for detection of prostate cancer. JAMA 1995;273:289-94.
234. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagen JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993;119:914-23.
235. Schroder FH. Prostate cancer: to screen or not to screen? Br Med J 1993;306:407-8.
236. Canadian Task Force on the Periodic Health Examination. The Canadian guide to clinical preventive health care. Ottawa, 1994; Health Canada Cat 21-117/1994E.
237. Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams and Wilkins, 1995.
238. American Urological Association Guidelines Development Group. Management of clinically localised prostate cancer. American Urological Association, 1995.
239. Call for action on prostate cancer. Report and recommendations from the 1997 National Prostate Cancer Forum; 1997 Feb 27-Mar 2; Toronto, Canada; Toronto: Canadian Cancer Society, 1997.